题目内容
The rather discouraging decade of the 1990s finished badly in September 1999 with the widely publicized death of Jesse Gelsinger, an 18-year-old man undergoing gene therapy for the kidney genetic disease ornithine transcarboxylase deficiency (OTCD) — a shadow over the whole field of gene-based therapies.
查看答案
搜索结果不匹配？点我反馈
更多问题
Since2003,5patientswithX-linkedseverecombinedimmunodeficiencydevelopedaleukemia-likesyndromenearly2.5-5yearsafterbeingtreatedwithretroviralgenetherapy.4outofthese5patientsareinremissionafterchemotherapyandingoodconditionwithdetectablegenemarkinginperipheralbloodcells.Initiationoftransformationwastracedbacktoinsertionalactivationoftheproto-oncogeneLMN2,atranscriptionalcofactor,whichinadditiontoitsroleinHSCdevelopment,promotesself-renewalofcommittedTcellswhenoverexpressedtherebyfacilitatingtheacquisitionofadditionalmutations.
Gendicine™ is a replicative virus and received approval for the treatment of head and neck squamous cell carcinoma.
The China's State Food and Drug Administration (SFDA) approved Gendicine in 2003 with data from a standard phase III clinical trial.
Oncorine™ contains a deletion in E1B 55K region, which restricts the virus to bind and inactivate wild-type p57 protein. Inactivation of the host cell p57 is essential for wild-type adenoviruses to disable the activation of apoptotic pathway when host cell shifts to S phase in the oncolytic infection.
微信支付 
支付宝支付